Skip to main content
SpringerLink
Log in

Abuse and Dependence Liability of GABAA-Receptor Modulators

Antecedents and Pharmacology

  • Chapter
The GABA Receptors

Part of the book series: The Receptors ((REC))

Abstract

Ligands that act at γ-aminobutyric type A (GABAA) receptors, in particular the benzodiazepines and related drugs, have broad clinical use but also the liability for abuse and dependence. Recent epidemiological data suggest that abuse of benzodiazepine-type drugs may be on the upswing, with a shift from primary misuse of benzodiazepines by people in a therapeutic setting to use by younger people engaging in recreational abuse. Laboratory findings suggest that benzodiazepine-type drugs have reinforcing effects both in human and non-human subjects. However, benzodiazepine-type drugs appear to have lower reinforcing effectiveness compared to other drugs of abuse, such as psychomotor stimulants. Recent research has begun to explore the role of GABAA receptor subtypes in the reinforcing effects of benzodiazepine-type drugs, and unlike other behavioral effects (e.g., motor coordination deficits); reinforcing effects are not easily attributed to a single receptor subtype. Perhaps the most firm conclusion that can be made at this point is that stimulation of GABAA receptors containing α1 subunits (α1GABAA receptors) is not necessary for self-administration of benzodiazepine-type compounds. Benzodiazepine use also is associated with physical dependence, characterized by a withdrawal syndrome. In both human and non-human subjects, this withdrawal syndrome is considered to be intermediate in severity. Preliminary results suggest that compounds with selectivity for α2GABAA, α3GABAA, and/or α5GABAA receptors do not induce physical dependence. As with reinforcing effects, systematic studies with selective compounds having relatively high intrinsic efficacy at particular subtypes should shed light on theses important mechanistic issues.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Höld, K. M., Sirisoma, N. S., Ikeda, T., Narahashi, T., and Casida, J. E. (2000) α-Thujone (the active component of absinthe): γ-Aminobutyric acid type A receptor modulation and metabolic detoxification. Proc. Natl. Acad. Sci. USA 97, 3826–3831.

    Article  PubMed  Google Scholar 

  2. Kumar, S., Fleming, R. L., and Morrow, A. L. (2004) Ethanol regulation of γ-aminobutyric acidA receptors: genomic and nongenomic mechanisms. Pharmacol. Ther. 101, 211–226.

    Article  PubMed  CAS  Google Scholar 

  3. Ator, N. A. and Griffiths, R. R. (1987) Self-administration of barbiturates and benzodiazepines: A review. Pharmacol. Biochem. Behav. 27, 391–398.

    Article  PubMed  CAS  Google Scholar 

  4. Tone, A. (2005) Listening to the past: history, psychiatry, and anxiety. Can. J. Psychiatry 50, 373–380.

    PubMed  Google Scholar 

  5. Woods, J. H. and Winger, G. (1995) Current benzodiazepine issues. Psychopharmacology 118, 107–115.

    Article  PubMed  CAS  Google Scholar 

  6. Nutt, D. J. (2005) Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr. 10, 49–56.

    PubMed  Google Scholar 

  7. Griffiths, R. R. (1995) Commentary on review by Woods and Winger. Benzodiazepines: long-term use among patients is a concern and abuse among polydrug abusers is not trivial. Psychopharmacology 118, 116–117.

    Article  PubMed  CAS  Google Scholar 

  8. Pritchett, D. B., Lüddens, H., and Seeburg, P. H. (1989) Type I and type II GABAA benzodiazepine receptor produced in transfected cells. Science 245, 1389–1392.

    Article  PubMed  CAS  Google Scholar 

  9. Löw, K., Crestani, F., Keist, R., et al. (2000) Molecular and neuronal substrate for the selective attenuation of anxiety. Science 290, 131–134.

    Article  PubMed  Google Scholar 

  10. McKernan, R. M., Rosahl, T. W., Reynolds, D. S., et al. (2000) Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor alpha1 subtype. Nature Neurosci. 3, 587–592.

    Article  PubMed  CAS  Google Scholar 

  11. Rudolph, U., Crestani, F., and Möhler, H. (2000) GABAA receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol. Sci. 22, 188–194.

    Article  Google Scholar 

  12. Rowlett, J. K., Platt, D. M., Lelas, S., Atack, J. R., and Dawson, G. R. (2005) Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. Proc. Natl. Acad. Sci. USA 102, 915–920.

    Article  PubMed  CAS  Google Scholar 

  13. McKernan, R. M. and Whiting, P. J. (1996) Which GABAA-receptor subtypes really occur in the brain? Trends Pharmacol. Sci. 19, 139–143.

    CAS  Google Scholar 

  14. Collinson, N., Kuenzi, F. M., Jarolimek, W., et al. (2002) Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the α5 subunit of the GABAA receptor J. Neurosci. 22, 5572–5580.

    PubMed  CAS  Google Scholar 

  15. Crestani, F., Keist, R., Fritschy, J. M., et al. (2002) Trace fear conditioning involves hippocampal α5 GABAA receptors. Proc. Natl. Acad. Sci. USA 99, 8980–8985.

    Article  PubMed  CAS  Google Scholar 

  16. Speaker, S. (1997) From “happiness pills” to “national nightmare”: changing cultural assessment of minor tranquilizers in America, 1955–1980. J. Hist. Med. Allied Sci. 52, 338–376.

    Article  PubMed  CAS  Google Scholar 

  17. Gordon, B. (1979) I’m Dancing as Fast as I Can. Harper & Row, New York, NY.

    Google Scholar 

  18. US Committee on Labor and Human Resources (1979) Use and misuse of benzodiazepines. Washington DC, US. Government Printing Office.

    Google Scholar 

  19. Ator, N. A. (2005) Contributions of GABAA receptor subtype selectivity to abuse liability and dependence potential of pharmacological treatments for anxiety and sleep disorders. CNS Spectr. 10, 31–39.

    PubMed  Google Scholar 

  20. Woods, J. H., Katz, J. L., and Winger, G. (1987) Benzodiazepines: Use, abuse, and consequences. Pharmacol. Rev. 39, 251–419.

    PubMed  CAS  Google Scholar 

  21. Woods, J. H., Katz, J. L., and Winger, G. (1992) Benzodiazepines: Use, abuse, and consequences. Pharmacol. Rev. 44, 151–347.

    PubMed  CAS  Google Scholar 

  22. Rosenbaum, J. F. (2005) Attitudes toward benzodiazepines over the years. J. Clin. Psychiatry 66, 4–8.

    PubMed  Google Scholar 

  23. Griffiths, R. R. and Weerts, E. M. (1997) Benzodiazepine self-administration in humans and laboratory animals — implications for problems of long-term use and abuse. Psychopharmacology 134, 1–37.

    Article  PubMed  CAS  Google Scholar 

  24. Griffiths, R. R. and Johnson, M. W. (2005) Relative abuse liability of hypnotic drugs: A conceptual framework and algorithm for differentiating among compounds. J. Clin. Psychiatry 66, 31–41.

    PubMed  CAS  Google Scholar 

  25. Crane, E. H. and Nemanski, N. (2004) Benzodiazepines in drug abuse-related emergency department visits: 1995–2002. The DAWN Report, April 2004, Office of Applied Studies, US Substance Abuse and Mental Health Services Administration (available online at http://dawninfo.samhsa.gov/). Last accessed: January 3, 2007.

    Google Scholar 

  26. Crane, E. H. and Nemanski, N. (2004) Demographic characteristics of benzodiazepine-involved ED visits. The DAWN Report, July 2004, Office of Applied Studies, US Substance Abuse and Mental Health Services Administration (available online at http://dawninfo.samhsa.gov/). Last accessed: January 3, 2007.

    Google Scholar 

  27. The DASIS Report (2005) Characteristics of primary tranquilizer admissions: 2002. Drug and Alcohol Services Information System, Office of Applied Studies, Substance Abuse and Mental Health Services Administration (available online at http://www.oas.samhsa.gov). Last accessed: January 3, 2007.

  28. Ciraulo, D. A., Sands, B. F., and Shader, R. I. (1988) Critical review of liability for benzodiazepine abuse among alcoholics. Am. J. Psychiatry 145, 1501–1506.

    PubMed  CAS  Google Scholar 

  29. de Wit, H. and Doty, P. (1993) Preference for ethanol and diazepam in light and moderate social drinkers: a within-subjects study. Psychopharmacology 115, 529–538.

    Article  Google Scholar 

  30. Evans, S. M., Griffiths, R. R., and de Wit, H. (1996) Preference for diazepam, but not buspirone, in moderate drinkers. Psychopharmacology 123, 154–163.

    Article  PubMed  CAS  Google Scholar 

  31. Sobel, K. G. and McCart, G. M. (1983) Drug use and accidental falls in an intermediate care facility. Drug Intell. Clin. Pharm. 17, 539–542.

    PubMed  CAS  Google Scholar 

  32. Herings, R. M., Stricker, B. H., de Boer, A., Bakker, A., and Sturmans, F. (1995) Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch. Intern. Med. 155, 1801–1807.

    Article  PubMed  CAS  Google Scholar 

  33. Ator, N. A. and Griffiths, R. R. (2003) Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend. 70, S55–S72.

    Article  PubMed  CAS  Google Scholar 

  34. Griffiths, R. R., Bigelow, G. E., and Ator, N. A. (2003) Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend. 70, S41–S54.

    Article  PubMed  Google Scholar 

  35. Lelas, S., Spealman, R. D., and Rowlett, J. K. (2000) Using behavior to elucidate receptor mechanisms: A review of the discriminative stimulus effects of benzodiazepines. Exp. Clin. Psychopharmacol. 8, 294–311.

    Article  PubMed  CAS  Google Scholar 

  36. Helmus, T. C., Tancer, M., and Johanson, C. E. (2005) Reinforcing effects of diazepam under anxiogenic conditions in individuals with social anxiety. Exp. Clin. Psychopharmacol. 13, 348–356.

    Article  PubMed  Google Scholar 

  37. Iguchi, M. Y., Handelsman, L., Bickel, W. K., and Griffiths, R. R. (1993) Benzodiazepine and sedative use/abuse by methadone maintenance clients. Drug Alcohol Depend. 32, 257–266.

    Article  PubMed  CAS  Google Scholar 

  38. Darke, S. G., Ross, J. E., and Hall, W. D. (1995) Benzodiazepine use among injecting heroin users. Med. J. Aust. 162, 645–647.

    PubMed  CAS  Google Scholar 

  39. Perera, K. M., Tulley, M., and Jenner, F. A. (1987) The use of benzodiazepines among drug addicts. Br. J. Addict. 82, 511–515.

    Article  PubMed  CAS  Google Scholar 

  40. Gelkopf, M., Bleich, A., Hayward, R., Bodner, G., and Adelson, M. (1999) Characteristics of benzodiazepine abuse in methadone maintenance treatment patients: a 1 year prospective study in an Israeli clinic. Drug Alcohol Depend. 55, 63–68.

    Article  PubMed  CAS  Google Scholar 

  41. Bergman, J. and Johanson, C. E. (1985) The reinforcing properties of diazepam under several conditions in the rhesus monkey. Psychopharmacology 86, 108–113.

    Article  PubMed  CAS  Google Scholar 

  42. Griffiths, R. R., Lamb, R. J., Sannerud, C. A., Ator, N. A., and Brady, J. V. (1991) Self-injection of barbiturates, benzodiazepines and other sedative-anxiolytics in baboons. Psychopharmacology 103, 154–161.

    Article  PubMed  CAS  Google Scholar 

  43. Broadbear, J. H., Winger, G., and Woods, J. H. (2005) Self-administration of methohexital, midazolam and ethanol: effects on the pituitary-adrenal axis in rhesus monkeys. Psychopharmacology 178, 83–91.

    Article  PubMed  CAS  Google Scholar 

  44. Winger, G., Stitzer, M. L., and Woods, J. H. (1975) Barbiturate-reinforced responding in rhesus monkeys: comparisons of drugs with different durations of action. J. Pharmacol. Exp. Ther. 195, 505–514.

    PubMed  CAS  Google Scholar 

  45. Rowlett, J. K., Rodefer, J. S., and Spealman, R. D. (2002) Self-administration of cocaine, alfentanil, and nalbuphine under progressive-ratio schedules: Consumer demand and labor supply analysis of relative reinforcing effectiveness. Exp. Clin. Psychopharmacol. 10, 367–375.

    Article  PubMed  CAS  Google Scholar 

  46. Weerts, E. M., Kaminski, B. J., and Griffiths, R. R. (1998) Stable low-rate midazolam self-injection with concurrent physical dependence under conditions of long-term continuous availability in baboons. Psychopharmacology 135, 70–81.

    Article  PubMed  CAS  Google Scholar 

  47. Griffiths, R. R., Sannerud, C. A., Ator, N. A., and Brady, J. V. (1992) Zolpidem behavioral pharmacology in baboons: self-injection, discrimination, tolerance and withdrawal. J. Pharmacol. Exp. Ther. 260, 1199–1208.

    PubMed  CAS  Google Scholar 

  48. Ator, N. A. (2000) Zaleplon and triazolam: drug discrimination, plasma levels, and self-administration in baboons. Drug Alcohol Depend. 24, 55–68.

    Article  Google Scholar 

  49. Atack, J. R., Wafford, K. A., Tye, S. J., et al. (2006) TPA023 [7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-30ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b] pyridazine], an agonist selective for α2 and α3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates. J. Pharmacol. Exp. Ther. 316, 410–422.

    Article  PubMed  CAS  Google Scholar 

  50. Dawson, G. R., Collinson, N., and Atack, J. R. (2005) Development of subtype selective GABAA modulators. CNS Spectr. 10, 21–27.

    PubMed  Google Scholar 

  51. Ashton, H. (1991) Protracted withdrawal syndromes from benzodiazepines. J. Subst. Abuse Treat. 8, 19–28.

    Article  PubMed  CAS  Google Scholar 

  52. Petursson, H. (1994) The benzodiazepine withdrawal syndrome. Addiction. 89, 1455–1459.

    Article  PubMed  CAS  Google Scholar 

  53. Mintzer, M. Z. and Griffiths, R. R. (2005) Flumazenil-precipitated withdrawal in healthy volunteers following repeated diazepam exposure. Psychopharmacology 178, 259–267.

    Article  PubMed  CAS  Google Scholar 

  54. O’Brien, C. P. (2005) Benzodiazepine use, abuse, and dependence. J. Clin. Psychiatry 66, 28–33.

    Article  PubMed  CAS  Google Scholar 

  55. Orsini, A., Brancato, V., and Smeraldi, E. (1990) Length of anxiolytic treatment and benzodiazepine withdrawal symptoms: a double blind study with clotiazepam. New Trends Exp. Clin. Psychiatry 6, 45–52.

    Google Scholar 

  56. Mintzer, M. Z., Stoller, K. B., and Griffiths, R. R. (1999) A controlled study of flumazenil-precipitated withdrawal in chronic low-dose benzodiazepine users. Psychopharmacology 147, 200–209.

    Article  PubMed  CAS  Google Scholar 

  57. Roth, T., Walsh, J. K., Krystal, A., Wessel, T., and Roehrs, T. A. (2005) An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med. 6, 487–495.

    Article  PubMed  Google Scholar 

  58. Martin, J. R., Moreau, J. L., Jenck, F., and Pieri, L. (1998) Sarmazenil-precipitated withdrawal: A reliable method for assessing dependence liability of benzodiazepine receptor ligands. Pharmacol. Biochem. Behav. 59, 939–944.

    Article  PubMed  CAS  Google Scholar 

  59. Kaminski, B. J., Sannerud, C. A., Weerts, E. M., Lamb, R. J., and Griffiths, R. R. (2003) Physical dependence in baboons chronically treated with low and high doses of diazepam. Behav. Pharmacol. 14, 331–342.

    PubMed  CAS  Google Scholar 

  60. Mirza, N. R. and Nielsen, E. Ø. (2006) Do subtype-selective GABAA receptor modulators have a reduced propensity to induce physical dependence in mice? J. Pharmacol. Exp. Ther. 316, 1378–1385.

    Article  PubMed  CAS  Google Scholar 

  61. Weerts, E. M., Ator, N. A., Grech, D. M., and Griffiths, R. R. (1998) Zolpidem physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons. J. Pharmacol. Exp. Ther. 285, 41–53.

    PubMed  CAS  Google Scholar 

  62. McMahon, L. R., Gerak, L. R., and France, C. P. (2001) Potency of positive γ-aminobutyric acidA modulators to substitute for a midazolam discriminative stimulus in untreated monkeys does not predict potency to attenuate a flumazenil discriminative stimulus in diazepam-treated monkeys. J. Pharmacol. Exp. Ther. 298, 1227–1235.

    PubMed  CAS  Google Scholar 

  63. Lukas, S. E. and Griffiths R. R. (1982) Precipitated withdrawal by a benzodiazepine receptor antagonist (Ro 15-1788) after 7 days of diazepam. Science 217, 1161–1163.

    Article  PubMed  CAS  Google Scholar 

  64. Grant, S. J., Galloway, M. P., Mayor, R., et al. (1985) Precipitated diazepam withdrawal elevates noradrenergic metabolism in primate brain. Eur. J. Pharmacol. 107, 127–132.

    Article  PubMed  CAS  Google Scholar 

  65. Gallager, D. W., Heninger, K., and Heninger, G. (1986) Periodic benzodiazepine antagonist administration prevents benzodiazepine withdrawal symptoms in primates. Eur. J. Pharmacol. 132, 31–38.

    Article  PubMed  CAS  Google Scholar 

  66. Lukas, S. E. and Griffiths, R. R. (1984) Precipitated diazepam withdrawal in baboons: effects of dose and duration of diazepam exposure. Eur. J. Pharmacol. 100, 163–171.

    Article  PubMed  CAS  Google Scholar 

  67. Sloan, J. W., Martin, W. R., and Wala, E. (1993) Effect of the chronic dose of diazepam on the intensity and characteristics of the precipitated abstinence syndrome in the dog. J. Pharmacol. Exp. Ther. 265, 1152–1162.

    PubMed  CAS  Google Scholar 

  68. Allison, C. and Pratt, J. A. (2003) Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence. Pharmacol. Ther. 98, 171–195.

    Article  PubMed  CAS  Google Scholar 

  69. Perrault, G., Morel, E., Sanger, D. J., and Zivkovic, B. (1992) Lack of tolerance and physical dependence upon repeated treatment with the novel hypnotic zolpidem. J. Pharmacol. Exp. Ther. 263, 298–303.

    PubMed  CAS  Google Scholar 

  70. Elliot, E. E. and White, J. M. (2000) Precipitated and spontaneous withdrawal following administration of lorazepam but not zolpidem. Pharmacol. Biochem. Behav. 66, 361–369.

    Article  PubMed  CAS  Google Scholar 

  71. Weerts, E. M. and Griffiths, R. R. (1998) Zolpidem self-injection with concurrent physical dependence under conditions of long-term continuous availability in baboons. Behav. Pharmacol. 9, 285–297.

    PubMed  CAS  Google Scholar 

  72. Ator, N. A., Weerts, E. M., Kaminski, B. J., Kautz, M. A., and Griffiths, R. R. (2000) Zaleplon and triazolam physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons. Drug Alcohol Depend. 61, 69–84.

    Article  PubMed  CAS  Google Scholar 

  73. Cowley, D. S., Roy-Byrne, P. P., Radant, A., et al. (1995) Benzodiazepine sensitivity in panic disorder: Effects of chronic alprazolam treatment. Neuropsychopharmacology 12, 147–157.

    Article  PubMed  CAS  Google Scholar 

  74. Stoops, W. W. and Rush, C. R. (2003) Differential effects in humans after repeated asministratios of zolpidem and triazlolam. Am. J. Drug Alcohol Abuse. 29, 281–299.

    Article  PubMed  Google Scholar 

  75. Smith, A. J., Alder, L., Silk, J., et al. (2001) Effect of a subunit on allosteric modulation of ion channel function in stably expressed human recombinant γ-aminobutyric acidA receptors determined using 36Cl ion flux. Mol. Pharmacol. 59, 1108–1118.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. New England Primate Research Center, Harvard Medical School, Southborough, MA

    James K. Rowlett PhD, Angela N. Duke MA & Donna M. Platt PhD

  2. Neuroscience and Behavior Program, University of Massachusetts, Amherst, MA

    James K. Rowlett PhD & Angela N. Duke MA

Authors
  1. James K. Rowlett PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Angela N. Duke MA
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Donna M. Platt PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Departments of Molecular and Integrative Physiology and of Pharmcology, Toxicology and Therapeutics, University of Kansas, Kansas City, KS

    S. J. Enna

  2. Department of Chemistry and Applied Biosciecnes Swiss Federal Institute of Technology (ETH), Institute of Pharmacology University of Zurich, Zurich

    Hanns Möhler

  3. Collegium Helveticum, Zurich, Switzerland

    Hanns Möhler

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Rowlett, J.K., Duke, A.N., Platt, D.M. (2007). Abuse and Dependence Liability of GABAA-Receptor Modulators. In: Enna, S.J., Möhler, H. (eds) The GABA Receptors. The Receptors. Humana Press. https://doi.org/10.1007/978-1-59745-465-0_7

Download citation

Publish with us

Policies and ethics

Search

Navigation